Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13081244 | 0.87 | SMN1; SMN2 (0.51) | GLASMN1; SMN2CSNK2A1BACE1BIRC5 | |
| SCHEMBL20718709 | 0.82 | ESR1 (0.42) | CSNK2A1KDM4EATMPPARGPPARA | |
| SCHEMBL13053296 | 0.75 | CYP3A4 (0.48) | SMN1; SMN2BACE1 | |
| SCHEMBL24038015 | 0.74 | GAA (0.46) | SMN1; SMN2CSNK2A1KDM4EATMHTR2B | |
| SCHEMBL26417555 | 0.74 | ESR1 (0.38) | KDM4EPPARGPPARA | |
| SCHEMBL23542720 | 0.74 | CSNK2A1 (0.40) | GLASMN1; SMN2CSNK2A1KDM4EATM | |
| SCHEMBL17703302 | 0.73 | ITGB3 (0.45) | SMN1; SMN2 | |
| SCHEMBL25986451 | 0.73 | ESR1 (0.39) | SMN1; SMN2KDM4EPPARGPPARA | |
| SCHEMBL12446453 | 0.72 | KDM4E (0.47) | SMN1; SMN2CSNK2A1KDM4EATMPPARA | |
| SCHEMBL13053303 | 0.71 | KCNH2 (0.48) | GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233976-B2 | Berbamine derivatives | CITY OF HOPE (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140155423-A1 | BERBAMINE DERIVATIVES | CITY OF HOPE (US) | 2014-06-05 | — | — | US | disclosed |
| US-8722698-B2 | Berbamine derivatives | CITY OF HOPE (US) | 2014-05-13 | — | — | US | disclosed |
| US-20100298369-A1 | BERBAMINE DERIVATIVES | CITY OF HOPE | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298369-A1 | BERBAMINE DERIVATIVES | BAK1, MCL1, BAD | GLA 2316/4885SMN1; SMN2 2251/4885CSNK2A1 3301/4885 |
| US-20140155423-A1 | BERBAMINE DERIVATIVES | BAK1, MCL1, BAD | GLA 2316/4885SMN1; SMN2 2251/4885CSNK2A1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.